Welcome to our dedicated page for First Wave BioPharma SEC filings (Ticker: FWBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
First Wave BioPharma filings document the registrant record reflected in recent reports under Entero Therapeutics, Inc., including common stock listed on the Nasdaq Capital Market under the ENTO symbol. The filing record includes Securities Act registration statements and amendments, 8-K material-event reports, and disclosures covering capital structure, security-holder rights, governance, and smaller reporting company status.
Recent filings describe matters such as common stock registration, reverse stock split implementation, annual meeting voting results, Nasdaq listing compliance, material agreements, executive and board changes, and clinical, regulatory, operating, and financial disclosures associated with the company’s biopharmaceutical business.